Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Major Shareholder Barry Canton Sells 37,650 Shares

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) major shareholder Barry Canton sold 37,650 shares of Ginkgo Bioworks stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $1.54, for a total value of $57,981.00. Following the completion of the transaction, the insider now directly owns 12,562,804 shares in the company, valued at $19,346,718.16. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Barry Canton also recently made the following trade(s):

• On Wednesday, October 18th, Barry Canton sold 37,650 shares of Ginkgo Bioworks stock. The stock was sold at an average price of $1.69, for a total value of $63,628.50.
• On Wednesday, October 11th, Barry Canton sold 37,650 shares of Ginkgo Bioworks stock. The stock was sold at an average price of $1.76, for a total value of $66,264.00.
• On Wednesday, September 27th, Barry Canton sold 37,650 shares of Ginkgo Bioworks stock. The stock was sold at an average price of $1.83, for a total value of $68,899.50.
• On Wednesday, September 6th, Barry Canton sold 37,650 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $2.23, for a total value of $83,959.50.
• On Wednesday, August 30th, Barry Canton sold 37,650 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $2.22, for a total value of $83,583.00.
• On Wednesday, August 23rd, Barry Canton sold 37,650 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $1.74, for a total value of $65,511.00.

Ginkgo Bioworks Price Performance

DNA opened at $1.52 on Friday. Ginkgo Bioworks Holdings, Inc. has a 1 year low of $1.12 and a 1 year high of $2.55. The stock has a 50-day moving average price of $1.64 and a 200-day moving average price of $1.76. The firm has a market cap of $3.19 billion, a PE ratio of -3.30 and a beta of 1.31.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on DNA shares. Raymond James lowered Ginkgo Bioworks from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $3.50 to $2.50 in a research report on Tuesday. BTIG Research cut shares of Ginkgo Bioworks from a “buy” rating to a “neutral” rating in a research report on Thursday, November 9th. One analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $3.19.

Institutional Trading of Ginkgo Bioworks

Institutional investors have recently bought and sold shares of the company. Yousif Capital Management LLC bought a new stake in shares of Ginkgo Bioworks in the second quarter worth approximately $25,000. Creative Planning bought a new position in Ginkgo Bioworks during the fourth quarter valued at approximately $25,000. Silverlake Wealth Management LLC bought a new position in Ginkgo Bioworks during the fourth quarter valued at approximately $25,000. Private Advisor Group LLC bought a new position in Ginkgo Bioworks during the first quarter valued at approximately $26,000. Finally, Endurance Wealth Management Inc. lifted its position in Ginkgo Bioworks by 100.0% during the first quarter. Endurance Wealth Management Inc. now owns 20,000 shares of the company’s stock valued at $27,000 after purchasing an additional 10,000 shares during the period. 56.84% of the stock is owned by hedge funds and other institutional investors.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.